Attribute development for a discrete choice experiment to examine preferences for long-acting HIV prevention products among pregnant and breastfeeding women
This paper documents a systematic attribute development process for a DCE assessing preferences for long-acting HIV prevention products among pregnant and breastfeeding women (PBFW) in Kenya. Through literature review and qualitative approaches, we identified twelve attributes for products formulated as oral tablets, injections, vaginal rings, and implants. Six of the twelve attributes were considered plausible, salient, and capable of being traded. A pilot among thirty PBFW confirmed the clarity and relevance of the six attributes, informing their inclusion in the DCE.
Resource Details
- Year
- 2026
- Population
- Breastfeeding Women, Pregnant Women
- Author
- Ngugi SM, Echoka E, Were V, Thuo N, Ogello V, Gikwa M, Muteti N, Mwangi P, Kazungu J, Ngure K.
- Source
- Scientific reports
More Publications & Resources
Providing PrEP to Pregnant and Breastfeeding Women
Clinical Practice Guidelines for Providing PrEP for Pregnant and Breastfeeding Populations
Guidelines on Lenacapavir for HIV Prevention and Testing Strategies for Long-Acting Injectable Pre-Exposure Prophylaxis
PrEP and PEP Guidelines-Zambia
PrEP Lenacapavir Implementation Guidelines
Provider Training Toolkit on Use of Oral and Long-acting HIV PrEP: Lenacapavir-Focused Learning Pathway (Lessons 1-4)
Provider Training Toolkit on Use of Oral and Long Acting HIV PrEP
Inclusion of Pregnant and Lactating People in the PURPOSE 1 Study: Efficacy, Safety, and Pharmacokinetics
Lenacapavir Provider Tools and Job Aids
PrEP Drug Interactions
Zambia PrEP Training Materials for Clinicians and Community Mobilisers
No results found.